In STEP 1-3 clinical trials, a weekly dose of 2.4 mg semaglutide resulted in a 49% reduction in C-reactive protein (CRP) levels, while a 1 mg weekly dose led to a 42% decrease, compared to placebo after 68 weeks
Further reinforcing this early and rapid inflammation reduction is that a lab measure called hsCRP, or high sensitivity C-reactive protein, was significantly reduced at 4 weeks as well, when patients had only lost 2.7% of their body weight
The disorder usually presents in early childhood and is characterized by episodes of hypoketotic hypoglycemia (that can cause encephalopathy), hepatomegaly, elevated liver enzymes (transaminases), and hypoammonemia in infants
This depends on your plan
What Is Prior Authorization for Mounjaro